These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27542969)

  • 1. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
    Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
    Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
    Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
    Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Bendrat K; Fritz P; Müller S; Brockmöller S; Debus A; Friedrichs K; Lindner C; Brinkmann F; Heidemann E; Niendorf A
    Anticancer Res; 2016 Aug; 36(8):3855-63. PubMed ID: 27466487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
    Gaudet MM; Campan M; Figueroa JD; Yang XR; Lissowska J; Peplonska B; Brinton LA; Rimm DL; Laird PW; Garcia-Closas M; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3036-43. PubMed ID: 19861523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
    Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
    Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma.
    Maekawa R; Mihara Y; Sato S; Okada M; Tamura I; Shinagawa M; Shirafuta Y; Takagi H; Taketani T; Tamura H; Sugino N
    J Ovarian Res; 2019 Feb; 12(1):14. PubMed ID: 30728052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.
    Babyshkina N; Vtorushin S; Zavyalova M; Patalyak S; Dronova T; Litviakov N; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
    Clin Exp Med; 2017 Aug; 17(3):383-393. PubMed ID: 27225751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
    Du X; Li XQ; Li L; Xu YY; Feng YM
    Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
    Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
    Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen impairs prepubertal mammary development and alters expression of estrogen receptor α (ESR1) and progesterone receptors (PGR).
    Tucker HL; Parsons CL; Ellis S; Rhoads ML; Akers RM
    Domest Anim Endocrinol; 2016 Jan; 54():95-105. PubMed ID: 26619291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy.
    Srivastava A; Sharma KL; Srivastava N; Misra S; Mittal B
    PLoS One; 2012; 7(7):e40162. PubMed ID: 22808109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR.
    Chen W; Zheng J; Wu C; Liu S; Chen Y; Liu X; Du J; Wang J
    Clin Chem; 2019 Aug; 65(8):1051-1059. PubMed ID: 31010819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor genotypes and haplotypes associated with breast cancer risk.
    Gold B; Kalush F; Bergeron J; Scott K; Mitra N; Wilson K; Ellis N; Huang H; Chen M; Lippert R; Halldorsson BV; Woodworth B; White T; Clark AG; Parl FF; Broder S; Dean M; Offit K
    Cancer Res; 2004 Dec; 64(24):8891-900. PubMed ID: 15604249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer.
    Medina-Jaime AD; Reyes-Vargas F; Martinez-Gaytan V; Zambrano-Galvan G; Portillo-Delcampo E; Burciaga-Nava JA; Reyes-Romero M; Sifuentes-Alvarez A
    Asian Pac J Cancer Prev; 2014; 15(7):3041-4. PubMed ID: 24815444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density.
    van Duijnhoven FJ; Peeters PH; Warren RM; Bingham SA; Uitterlinden AG; van Noord PA; Monninkhof EM; Grobbee DE; van Gils CH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):462-7. PubMed ID: 16537702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.